Clay Crockett
Psychiatric/Mental Health · Gilbert, AZNPI 1164120150
Payments from drug & device makers
Across 47 payments — averaging $95.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$872
- Otsuka America Pharmaceutical, Inc.$277
- Alkermes, Inc.$252
- Axsome Therapeutics, Inc.$240
- AbbVie$210
- plus $397 from 5 others
What the payments were for
- Consulting fees$1,76039%
- Travel & lodging$1042%
- Food & beverage$2,60958%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 6 | $2,225 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $872 |
| Otsuka America Pharmaceutical, Inc. | 4 | $277 |
| Alkermes, Inc. | 4 | $252 |
| Axsome Therapeutics, Inc. | 2 | $240 |
| AbbVie | 6 | $210 |
| Vanda Pharmaceuticals Inc. | 2 | $141 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Lundbeck LLC | 2 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$465
- LYBALVI$404
- COBENFY$256
- Auvelity$240
- Fanapt$125
- VRAYLAR$124
- ABILIFY MAINTENA$124
- ABILIFY ASIMTUFII$124
- Austedo XR$121
How this compares
$4,472 in reported general payments places this provider in the 90th percentile of 1,230 psychiatric/mental health providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 11 | $1,664 |
| Bupropion XlBupropion Hcl | 57 | $1,074 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 34 | $889 |
| Quetiapine Fumarate | 21 | $872 |
| Lamotrigine | 50 | $677 |
| Trazodone Hcl | 62 | $625 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $598 |
| Duloxetine Hcl | 31 | $561 |
| Hydroxyzine Hcl | 29 | $508 |
| Olanzapine | 24 | $425 |
| Bupropion Hcl SrBupropion Hcl | 16 | $404 |
| Risperidone | 19 | $351 |
| Aripiprazole | 14 | $307 |
| Hydroxyzine Pamoate | 17 | $271 |
| Gabapentin | 17 | $262 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Gilbert
- Diane StrickerGilbert$281K
- Roya NayeriGilbert$15K
- Ann CaseyGilbert$7K
- Nicole LyonsGilbert$7K
- Landis StokumGilbert$7K
- Jeffrey ScottGilbert$7K
- Rachel EagerGilbert$7K
- Marcus DanielsGilbert$6K
- Sarah ButtlesGilbert$6K
- Melanie LaubGilbert$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.